Sharon Friedlander

1.3k total citations
35 papers, 748 citations indexed

About

Sharon Friedlander is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Sharon Friedlander has authored 35 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Hematology. Recurrent topics in Sharon Friedlander's work include Nuclear Structure and Function (19 papers), Ubiquitin and proteasome pathways (8 papers) and Acute Myeloid Leukemia Research (6 papers). Sharon Friedlander is often cited by papers focused on Nuclear Structure and Function (19 papers), Ubiquitin and proteasome pathways (8 papers) and Acute Myeloid Leukemia Research (6 papers). Sharon Friedlander collaborates with scholars based in United States, Canada and Japan. Sharon Friedlander's co-authors include Gerald C. Chu, Eric L. Snyder, Tyler Jacks, Denise Crowley, Nomeda Girnius, Eliza Vasile, Ronald A. DePinho, Sharon Shacham, Michael Kauffman and Yosef Landesman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Sharon Friedlander

34 papers receiving 742 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sharon Friedlander United States 10 437 333 146 124 120 35 748
Hong Xie United States 13 338 0.8× 406 1.2× 252 1.7× 91 0.7× 135 1.1× 29 739
Charlotte Lemech Australia 16 262 0.6× 389 1.2× 108 0.7× 114 0.9× 78 0.7× 63 695
Valérie Méresse France 13 314 0.7× 335 1.0× 218 1.5× 103 0.8× 48 0.4× 23 830
Timothy Larson United States 14 373 0.9× 447 1.3× 85 0.6× 271 2.2× 60 0.5× 30 792
Anil Sadarangani United States 15 648 1.5× 183 0.5× 149 1.0× 54 0.4× 80 0.7× 32 970
Davide Torti Italy 12 418 1.0× 304 0.9× 63 0.4× 116 0.9× 34 0.3× 17 677
Zizhen Feng China 12 671 1.5× 272 0.8× 51 0.3× 140 1.1× 137 1.1× 23 1.0k
Paul A. Algate United States 7 269 0.6× 146 0.4× 68 0.5× 112 0.9× 62 0.5× 12 528
Dan Lu China 9 458 1.0× 203 0.6× 52 0.4× 85 0.7× 39 0.3× 16 694
Mitsuyo Yoshihara Japan 18 341 0.8× 295 0.9× 47 0.3× 271 2.2× 130 1.1× 37 868

Countries citing papers authored by Sharon Friedlander

Since Specialization
Citations

This map shows the geographic impact of Sharon Friedlander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon Friedlander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon Friedlander more than expected).

Fields of papers citing papers by Sharon Friedlander

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sharon Friedlander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon Friedlander. The network helps show where Sharon Friedlander may publish in the future.

Co-authorship network of co-authors of Sharon Friedlander

This figure shows the co-authorship network connecting the top 25 collaborators of Sharon Friedlander. A scholar is included among the top collaborators of Sharon Friedlander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon Friedlander. Sharon Friedlander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Dudek, Arkadiusz Z., Dejan Juric, Afshin Dowlati, et al.. (2021). 476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results. Regular and Young Investigator Award Abstracts. A505–A506. 10 indexed citations
3.
Adès, Lionel, Justin M. Watts, Atanas Radinoff, et al.. (2020). PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777). Hematology Transfusion and Cell Therapy. 42. 285–286. 1 indexed citations
4.
5.
Berger, Allison, Sharon Friedlander, Omid Ghasemi, et al.. (2019). Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model. Cancer Research. 79(13_Supplement). 3079–3079. 4 indexed citations
6.
Berger, Allison, Sharon Friedlander, Omid Ghasemi, et al.. (2019). Abstract 3079: Pharmacodynamic evaluation of the novel SUMOylation inhibitor TAK-981 in a mouse tumor model. 3079–3079. 1 indexed citations
7.
Kuruvilla, John, Michael R. Savona, Rachid Baz, et al.. (2017). Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 129(24). 3175–3183. 112 indexed citations
8.
Argueta, Christian, Trinayan Kashyap, Boris Klebanov, et al.. (2017). Abstract 329: Selinexor or KPT-8602 mediated XPO1 inhibition synergizes with dexamethasone to repress convergent pathways in the mTORC1 signaling network and drive cell death in multiple myeloma. Cancer Research. 77(13_Supplement). 329–329. 3 indexed citations
9.
Fischer, Melissa A., Sharon Friedlander, Leah J. Hogdal, et al.. (2016). Combination of Selective Inhibitor of Nuclear Export (SINE) Compounds, Selinexor and KPT-8602, with Venetoclax (ABT-199) Displays Enhanced Activity in Leukemia and Large Cell Lymphoma. Blood. 128(22). 3949–3949. 5 indexed citations
10.
Mau‐Sørensen, Morten, Scott R. Plotkin, Patrick Y. Wen, et al.. (2016). A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology. 34(15_suppl). 2077–2077. 6 indexed citations
11.
12.
Cornell, Robert F., Adriana Rossi, Rachid Baz, et al.. (2016). A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma. Blood. 128(22). 4509–4509. 8 indexed citations
13.
Cesare, Michelandrea De, Denis Cominetti, Valentina Doldi, et al.. (2015). Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin. Oncotarget. 6(15). 13119–13132. 40 indexed citations
14.
15.
Rashal, Tami, Sivan Elloul, Marsha Crochiere, et al.. (2015). Abstract 4490: Selinexor (KPT-330) radio-sensitizes non-small cell lung cancer cells in vitro and in vivo. Cancer Research. 75(15_Supplement). 4490–4490. 1 indexed citations
16.
Tan, David S.P., Wei Peng Yong, Ross A. Soo, et al.. (2015). Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.. Journal of Clinical Oncology. 33(15_suppl). 2542–2542. 3 indexed citations
17.
Wettersten, Hiromi I., Yosef Landesman, Sharon Friedlander, et al.. (2014). Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth. PLoS ONE. 9(12). e113867–e113867. 23 indexed citations
18.
Shipitsin, Michail, Eldar Giladi, Sharon Friedlander, et al.. (2014). Identification of proteomic biomarkers predicting prostate cancer aggressiveness and lethality despite biopsy-sampling error. British Journal of Cancer. 111(6). 1201–1212. 104 indexed citations
19.
Gounder, Mrinal M., Herbert H. Loong, Yelena Ustoyev, et al.. (2014). A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas.. Journal of Clinical Oncology. 32(15_suppl). 10587–10587. 1 indexed citations
20.
Friedlander, Sharon, Gerald C. Chu, Eric L. Snyder, et al.. (2009). Context-Dependent Transformation of Adult Pancreatic Cells by Oncogenic K-Ras. Europe PMC (PubMed Central). 249 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hong Xie Breakdown of academic impact, for papers by Charlotte Lemech Breakdown of academic impact, for papers by Valérie Méresse Breakdown of academic impact, for papers by Timothy Larson Breakdown of academic impact, for papers by Anil Sadarangani Breakdown of academic impact, for papers by Davide Torti Breakdown of academic impact, for papers by Zizhen Feng Breakdown of academic impact, for papers by Paul A. Algate Breakdown of academic impact, for papers by Dan Lu Breakdown of academic impact, for papers by Mitsuyo Yoshihara
Rankless by CCL
2026